High-strength testosterone undecanoate compositions
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C max to serum testosterone C ave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration C ave range for a male subject is provided.
1. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising:
orally administering, twice a day with food, to a male identified as having a morning serum testosterone level of less than 300 ng/dL, a daily dosing regimen of a pharmaceutical composition comprising testosterone undecanoate in an amount of about 15-20 weight % (wt %) of the composition and a carrier comprising polyoxyl vegetable oil in an amount of from 8-16 wt % of the composition and maize oil monoglycerides in an amount of from 63-68 wt % of the composition, that provides about 450 mg of testosterone undecanoate to said male per day, determining the serum level of testosterone of said male after administration of said pharmaceutical composition at steady state; and orally administering to said male a quantity of said pharmaceutical composition twice a day with food to provide a serum testosterone Cave in said male in the range of from about 300-1100 ng/dL and a Cmax of less than about 2500 ng/dL, wherein said quantity is based on said determined serum level of testosterone of said male after said administration of said pharmaceutical composition at steady state.
2. The method of claim 1 , wherein said carrier further comprises glyceryl monolinoleate.
3. The method of claim 1 , wherein said carrier further comprises oleic acid.
4. The method of claim 2 , said carrier comprises a hydrophilic surfactant.
5. The method of claim 3 , said carrier comprises a hydrophilic surfactant.
6. The method of claim 1 , wherein at least one administration of said pharmaceutical composition is administered as 2 capsules having about 225 mg of testosterone undecanoate.
7. The method of claim 4 , wherein at least one administration of said pharmaceutical composition is administered as 1 capsule having about 225 mg of testosterone undecanoate.
8. The method of claim 5 , wherein at least one administration of said pharmaceutical composition is administered as 1 capsule having about 225 mg of testosterone undecanoate.
9. The method of claim 1 , wherein single dose administration of said pharmaceutical composition provides a serum testosterone Cmax to Cave ratio of 2.7 or less.
10. The method of claim 3 , wherein single dose administration of said pharmaceutical composition provides a serum testosterone Cmax to Cave ratio of 2.7 or less.
11. The method of claim 4 , wherein single dose administration of said pharmaceutical composition provides a serum testosterone Cmax to Cave ratio of 2.7 or less.
12. The method of claim 5 , wherein single dose administration of said pharmaceutical composition provides a serum testosterone Cmax to Cave ratio of 2.7 or less.
13. The method of claim 9 , wherein single dose administration of said pharmaceutical composition provides a dose normalized serum testosterone Cave of greater than 1.9×10-6 dL-1.
14. The method of claim 10 , wherein single dose administration of said pharmaceutical composition provides a dose normalized serum testosterone Cave of greater than 1.9×10-6 dL-1.